血小板聚集功能监测现状
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2014年第4期
- 页码:
- 494-F004
- 栏目:
- 综述
- 出版日期:
- 2014-04-25
文章信息/Info
- Title:
- Current status of research on monitoring of platelet aggregation function
- Author(s):
- CUI Mei-hong; WEI Yu-jie; LIU Hui-liang
- （Department of Cardiology, General Hospital, Armed Police Forces, Beijing 10039, China）
- 分类号:
- R331.143
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 抗血小板药物存在很大的个体差异性，一部分患者接受抗血小板药物治疗后，仍然存在血小板高反应性(HPR)，而HPR跟不良临床结果相关。因此，学者们提出，运用血小板聚集功能监测来指导抗血小板治疗，并开展了许多关于这方面的研究，但却得出两个相悖的结论。为此，未来还需要设计更完善的研究来验证血小板功能检测的临床意义。
- Abstract:
- The platelet inhibitory effect of antiplatelet agents varies widely among individuals. Some of the patients receiving antiplatelet drugs still have high platelet reactivity and high platelet reactivity is associated with adverse clinical outcomes. Platelet aggregation function monitoring has been proposed to guide antiplatelet therapy. In recent years, research has been performed to evaluate the clinical impact of more intensive antiplatelet therapy based on platelet reactivity testing, but two opposite conclusions have been drawn. Better research should be designed to verify the clinical significance of platelet function testing.
参考文献/References
[1]Wright RS,Anderson JL,Adams CD,et al.2011ACCF/AHA focused update of the Guidelines for the management of patients with un-stable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians,Society for Cardiovascular Angiography and Intervention,and Society of Thoracic Surgeons[J].J Am Coll Cardiol,2011,57(19):1960.
[2]Sofi F,Marcucci R,Gori AM,et al.Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis[J]. Thromb Haemostasis,2010,103(4):841-848.
[3]Breet NJ,van Werkum JW,Bouman HJ,et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J].JAMA,2010,303(8):754-762.
[4]Sibbing D,Braun S,Jawansky S,et al.Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment[J].Thromb Haemost,2008,99(1):121-126.
[5]Sibbing D,Braun S,Morath T,et al.Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis[J].J Am Coll Cardiol,2009,53(10):849-856.
[6]Ranucci M,Baryshnikova E,Soro G,et al.Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines［J］. Ann Thorac Surg,2011,91(1):123-129.
[7]Sibbing D,Morath T,Braun S,et al.Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting[J].Thromb Haemost,2010,103(1):151-159.
[8]van Werkum JW,Kleibeuker M,Postma S,et al.A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel[J].Int J Cardiol,2010,140(1):123-126.
[9]Van Cott EM.Point-of-care testing in coagulation[J].Clin Lab Med,2009,29(3):543-553.
[10]Price MJ,Berger PB,Teirstein PS,et al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J].JAMA,2011,305(11):1097-1105.
[11]Gurbel PA,Erlinge D,Ohman EM,et al.Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization:the TRILOGY ACS platelet function substudy[J].JAMA,2012,308(17):1785-1794.
[12]Collet JP,Cuisset T,Rangé G,et al.Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J].N Engl J Med,2012,367(22):2100-2109.
[13]Marcucci R,Gori AM,Paniccia R,et al.Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up[J].Circulation,2009,119(2):237-242.
[14]Ahn SG,Lee SH,Yoon JH,et al.Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction[J].JACC Cardiovasc Interv,2012,5(3):259-267.
[15]Trenk D,Stone GW,Gawaz M,et al.A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents:Results of the TRIGGER-PCI(Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel)study[J].J Am Coll Cardiol,2012,59(24):2159-2164.
[16]Bonello L,Camoin-Jau L,Armero S,et al.Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis[J].Am J Cardiol,2009, 103(1):5-10.
[17]Hazarbasanov D,Velchev V,Finkov B,et al.Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention[J].J Thromb Thrombolysis,2012,34(1):85-90.
[18]Siller-Matula JM,Francesconi M,Dechant C,et al.Personalized antiplatelet treatment after percutaneous coronary intervention: the Madonna study[J].Int J Cardiol,2013,167(5):2018-2023.
[19]Aradi D,Rideg O,Vorobcsuk A,et al.Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity[J].Eur J Clin Invest,2012,42(4):384-392.
[20]Wang XD,Zhang DF,Zhuang SW,et al.Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance[J].Clin Cardiol,2011,34(5):332-338.
[21]Ari H,Ozkan H,Karacinar A,et al.The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial)[J].Int J Cardiol,2012,157(3):374-380.
[22]Aradi D,Komócsi A,Price MJ,et al.Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention:systematic review and meta-analysis[J].Int J Cardiol,2013,167(5): 2140-2148.
[23]Trenk D,Stone GW,Gawaz M,et al.A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of Drug-Eluting StentsResults of the TRIGGER-PCI(testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel)study[J].J Am College Cardiol,2012,59(24):2159-2164.
[24]Aradi D,Sibbing D,Bonello L.Current evidence for monitoring platelet reactivity in acute coronary syndrome:a plea for individualized antiplatelet treatment[J].Int J Cardiol,2013,167(5):1794-1797.
[25]Siller-Matula JM,Jilma B.Why have studies of tailored anti-platelet therapy failed so far?[J].Thromb Haemost,2013,110(4):628-631.
[26]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary:a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions[J].Circulation,2011,124(23):2574-2609.
[27]Hamm CW,Bassand JP,Agewall S,et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:the task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European society of cardiology(ESC)[J].Eur Heart J,2011,32(23):2999-3054.
备注/Memo
- 备注/Memo:
- 收稿日期：2013-12-25.通讯作者：刘惠亮，主任医师，主要从事心血管介入研究 Email：huiliangl531@163.com 作者简介：崔美红，硕士生 Email：cuimeihong2010@126.com
常用功能
统计/Statistics
- 摘要浏览/Viewed737
- 评论/Comments
